뉴스벤징가
ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment
· 발표
기사 요약
New data show ImmunityBio's ANKTIVA combined with BCG provides durable responses and high survival rates in unresponsive bladder cancer.
기사 원문에서 발췌했어요.New data show ImmunityBio's ANKTIVA combined with BCG provides durable responses and high survival rates in unresponsive bladder cancer.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…